We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly Inks Deal With Merus Worth Up to $1.6 Billion to Develop Cancer Drugs
Eli Lilly Inks Deal With Merus Worth Up to $1.6 Billion to Develop Cancer Drugs
Eli Lilly has agreed to pay Dutch drugmaker Merus up to $1.6 billion to develop novel T-cell re-directing bispecific antibodies for treating various cancers.